A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies

Recruiting

Phase 1

Phase 2

REGN10597A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies

Sponsor:

Regeneron Pharmaceuticals

Code:

NCT06413680

Conditions

Melanoma

Clear-Cell Renal-Cell Carcinoma (ccRCC)

Advanced Solid Tumors

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

REGN10597

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-01. This information was provided to ClinicalTrials.gov by Regeneron Pharmaceuticals on 2025-04-01.